Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : REV102
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Recursion Pharma
Deal Size : $25.0 million
Deal Type : Agreement
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
Details : Rallybio sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia (HPP) to Recursion.
Product Name : REV102
Product Type : Other Small Molecule
Upfront Cash : $7.5 million
July 08, 2025
Lead Product(s) : REV102
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Recursion Pharma
Deal Size : $25.0 million
Deal Type : Agreement
Lead Product(s) : RLYB212
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
Details : RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 08, 2025
Lead Product(s) : RLYB212
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RLYB212
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
Details : RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 11, 2025
Lead Product(s) : RLYB212
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RLYB116
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : RLYB116
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RLYB-212
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
Details : RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : RLYB-212
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RLYB-212
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rallybio Starts Phase 2 RLYB212 Trial for Pregnant Women At Risk of FNAIT
Details : RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : RLYB-212
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RLYB-212
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $6.6 million
Deal Type : Collaboration
Rallybio Collaborates on Solutions for Fetal Alloimmune Thrombocytopenia
Details : Under this collaboration, Johnson & Johnson will fund Rallybio's RLYB212, the sole investigational therapy aimed at addressing the needs of pregnant individuals at risk of FNAIT.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
October 04, 2024
Lead Product(s) : RLYB-212
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $6.6 million
Deal Type : Collaboration
Lead Product(s) : RLYB212
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : RLYB212
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RLYB-116
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RLYB116 is a novel antibody mimetic fusion protein, long-acting C5 inhibitor. It is being evaluated in phase 1 clinical trials for patients with complement-mediated diseases.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : RLYB-116
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RLYB-212
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RLYB212, an anti-HPA-1a monoclonal antibody and once monthly subcutaneous administration, being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 28, 2023
Lead Product(s) : RLYB-212
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable